Sharsti Sandall
Executive Director, Oncology Research Pfizer
Seminars
Wednesday 5th November 2025
The Way Forward: What’s the New Path to the Next-Generation of ADCs?
12:30 pm
- Understanding how to migrate from non-selective ADC payloads
- Debating the right properties for a next generation payload and linker: Can (or should?) any small molecule therapeutic be developed into an ADC?
- Debating the right strategy for dual-payload ADCs
- Understanding ADC toxicity and developability for next-generation conjugates
Monday 3rd November 2025
Chair:
As ADCs become more crowded with Topo1 and MMAE payloads across oncology indications, the need for ADC differentiation across payload and targeting moieties is crucial to overcome patient resistance and provide long-term patient benefit.
Join this seminar day to stay ahead of the ADC design curve across non-cytotoxic payloads, site-specific conjugation technologies, and emerging multi payload ADC design rationale and performance
Download the Full Event Guide for full details
